Cellulitis and cutaneous abscesses represent common skin and soft tissue infections caused predominantly by gram-positive bacteria. While both conditions share overlapping risk factors and pathogens, their clinical presentations, diagnostic requirements, and definitive management strategies differ significantly.
Clinical Concept: Severe or complicated cellulitis can present with systemic symptoms such as fever, malaise, chills, lymphangitic spread, and pain disproportionate to physical examination findings. Additionally, community-acquired MRSA (CA-MRSA) lesions with dark or necrotic centers are often mistakenly attributed to spider bites—specifically the brown recluse spider (Loxosceles reclusa).
Cellulitis is an acute infection of the skin and subcutaneous tissue. It typically originates from a disruption in skin integrity, such as an insect bite, surgical incision, abrasion, or other cutaneous trauma, and occurs most commonly on the extremities.
A cutaneous abscess is a skin and soft tissue infection that results in a localized collection of purulent fluid within the dermis or subcutaneous space. Key contributors include cutaneous trauma, dermal bacterial overgrowth, immunosuppression, and impaired circulation.
Uncomplicated cellulitis (limited area, minimal pain, no systemic signs) and small, uncomplicated abscesses in healthy patients generally do not require diagnostic testing. Diagnostic workup is indicated for complicated or severe presentations:
| Condition | Indication for Testing | Recommended Diagnostic Workup |
|---|---|---|
| Cellulitis | Complicated disease, systemic toxicity, or severe pain. | CBC with differential, blood cultures, serum creatinine, bicarbonate, creatine phosphokinase (CPK), and C-reactive protein (CRP). |
| Abscess | Severe infection, systemic signs, recurrent/multiple abscesses, treatment failure, extremes of age, or underlying comorbidities (e.g., diabetes, immunosuppression, malignancy). | Wound aspiration/abscess culture and susceptibility testing, alongside blood cultures. |
Management depends on infection severity, presence of purulence or necrosis, MRSA risk, and systemic involvement:
| Category / Condition | Management & Antimicrobial Options | Clinical Considerations |
|---|---|---|
| Cellulitis (Low MRSA Risk) | Oral Dicloxacillin, Cephalexin, or Azithromycin (if penicillin-allergic). | Systemic coverage focused on streptococcal and MSSA strains. Adjunctive care: warm compresses, limb rest, and elevation. Clinical improvement expected in 48–72 hours. |
| Cellulitis (High MRSA Risk or Surrounding Furunculosis/Abscess) | TMP-SMX (Bactrim®) PLUS a Beta-lactam (e.g., Cephalexin), or Doxycycline, Clindamycin. | TMP-SMX covers CA-MRSA well, but its streptococcal coverage is uncertain. Combining TMP-SMX with a beta-lactam ensures dual coverage against staphylococci and streptococci. |
| Recurrent Cellulitis Prevention | Protracted antimicrobial prophylaxis (weeks to months); examine and treat interdigital toe spaces for scaling, maceration, or fissuring. | Eradicates pathogen colonization in patients with lower-extremity edema, diabetes, or venous insufficiency. |
| Abscess (< 5 cm, Afebrile Patient) | Incision and drainage (I&D) + localized care (warm soaks). Wound culture recommended. | First-line primary treatment. Antimicrobial therapy is generally unnecessary for small, localized abscesses without systemic signs. |
| Abscess (≥ 5 cm or Complicated) | Incision and drainage PLUS oral antibiotics: TMP-SMX, Doxycycline, or Clindamycin. Linezolid (Zyvox®) is an effective oral option for severe cases. | Selection must target CA-MRSA. Standard beta-lactams and macrolides are ineffective against CA-MRSA. Linezolid is reserved for refractory cases or complex comorbidities due to cost. |
| Inpatient Parenteral Therapy (Cellulitis or Abscess) | Standard Parenteral: Vancomycin, Daptomycin, Linezolid. Long-acting/Newer: Dalbavancin (2 weekly doses), Oritavancin (single dose), Telavancin, Ceftaroline. | Indicated for SIRS, hemodynamic instability, mental status changes, or immunocompromised hosts. Long-acting lipoglycopeptides (dalbavancin, oritavancin) offer convenient outpatient transition. |
1. Barankin B, Anatoli F. Derm Notes: Clinical Dermatology Pocket Guide. Philadelphia, PA: F.A. Davis; 2006.
2. Gilbert DN, Chambers HF, Eliopoulos GM, Saag M, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 50th ed. Sperryville, VA: Antimicrobial Therapy, Inc.; 2020:55, 86.
3. Stevens DL. Bacterial diseases of the skin. In: Bope ET, Kellerman RD, eds. Conn’s Current Therapy 2018. Philadelphia, PA: Elsevier; 2018:924–927.
